BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 3157927)

  • 1. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW; Schally AV
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1985 Apr; 82(8):2498-502. PubMed ID: 3157990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
    Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
    Zalatnai A; Paz-Bouza JI; Redding TW; Schally AV
    Prostate; 1988; 12(1):85-98. PubMed ID: 2894651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.
    Schally AV; Redding TW; Comaru-Schally AM
    Med Oncol Tumor Pharmacother; 1984; 1(2):109-18. PubMed ID: 6242477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
    Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
    Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6509-12. PubMed ID: 6458815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of flutamide action on prostatic and testicular functions in the rat.
    Marchetti B; Labrie F
    J Steroid Biochem; 1988 Jun; 29(6):691-8. PubMed ID: 2838689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.
    Redding TW; Schally AV; Tice TR; Meyers WE
    Proc Natl Acad Sci U S A; 1984 Sep; 81(18):5845-8. PubMed ID: 6237365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH.
    Schally AV; Redding TW; Comaru-Schally AM
    Prostate; 1983; 4(6):545-52. PubMed ID: 6226942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological findings in the rat prostate cancer model during treatment with a luteinizing hormone-releasing hormone agonist and novantrone.
    Paz-Bouza JI; Schor NA; Monje E; Redding TW; Schally AV
    Prostate; 1987; 10(4):291-302. PubMed ID: 2955293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
    Mathé G; Schally AV; Comaru-Schally AM; Mauvernay RY; Vovan ML; Machover D; Misset JL; Court B; Bouchard P; Duchier J
    Prostate; 1986; 9(4):327-42. PubMed ID: 2947053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
    Torres-Aleman I; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.